Table 1.

Clinical and treatment characteristics of the matched METABRIC cohorts

Matching variablesaRadiation-sensitiveRadiation-resistantPImmune-effectiveImmune-defectivePRadiation-sensitive, immune-effectiveRadiation-resistant, immune-effective or radiation-sensitive, immune-defectiveRadiation-resistant, immune-defectiveP
Total no.322202180348126236152
Age ≥ 50 years280 (87%)168 (83%)0.28148 (82%)296 (85%)0.47102 (80%)208 (88%)124 (82%)0.10
ER positive282 (88%)154 (76%)0.001176 (98%)262 (75%)<0.001124 (98%)190 (81%)110 (72%)<0.001
HER2 positive10 (3%)52 (26%)<0.0012 (1%)56 (16%)<0.0012 (2%)12 (5%)44 (29%)<0.001
Stage<0.0010.710.004
 02 (1%)0 (0%)0 (0%)2 (<1%)0 (0%)2 (<1%)0 (0%)
 186 (27%)36 (18%)44 (24%)82 (24%)30 (24%)72 (31%)24 (16%)
 2228 (71%)142 (70%)126 (70%)242 (70%)92 (73%)152 (64%)112 (74%)
 36 (2%)22 (11%)10 (6%)20 (6%)4 (4%)10 (4%)14 (9%)
 40 (0%)2 (1%)0 (0%)2 (<1%)0 (0%)0 (0%)2 (1%)
Received hormone therapy258 (80%)144 (71%)0.03150 (83%)256 (74%)0.02102 (81%)186 (79%)104 (68%)0.02
Received chemotherapy26 (8%)42 (21%)<0.00110 (6%)58 (17%)0.00110 (8%)18 (8%)38 (25%)<0.001
Surgery type0.0210.10
 Mastectomy242 (75%)170 (84%)142 (79%)276 (79%)94 (75%)180 (76%)128 (84%)
 BCS80 (25%)32 (16%)38 (21%)72 (21%)32 (25%)56 (24%)24 (16%)
  • aDue to the exact matching within each of the 7 groups (radiation-sensitive etc.), the matching variables had identical distributions comparing patients who received RT versus those who did not.